Abstract: ObjectiveTo compare the curative effects and safety of zotarolimuseluting stents (ZES) and sirolimuseluting stents (SES) after percutaneous coronary intervention(PCI). MethodsThe databases of Pubmed， Embase， Chocorane library， Science Direct， CNKI，Chinese Biological Medical Disc and related website such as http://scholar.google.com/ were retrieved with computer for collecting randomized controlled trials (RCTs) about the comparison in the curative effects and safety of ZES and SES published from inception to Jan 31， 2016. After critical appraisal for the literature quality using the Cochrane Reviewers Handbook， the eligible data of RCTs were extracted and given a metaanalysis by applying RevMen 5.3 software. ResultsThere were nine RCTs identified (a total of 6 672 patients)， the treatment group had 3 434 cases and the control group had 3 238 cases. Metaanalysis showed that there was no statistical difference between ZES group and SES group in the incidence of mortality (RR=0.99，95%CI=0.831.19，P=0.93)， cardiac mortality (RR=0.86，95%CI=0.631.19，P=0.37)， MACE (RR=1.05，95%CI=0.931.20，P=0.43)， myocardial infarction (RR=0.84， 95%CI=0.681.02，P=0.08)， target vessel revascularization (RR=1.19，95%CI=0.991.42，P=0.06) and stent thrombosis (RR=0.82，95%CI=0.461.46，P=0.50). There was statistically significant difference between two groups in the rate of target lesion revascularization (RR=1.49，95%CI=1.181.89，P=0.0008). ConclusionData showed that two kinds of drugeluting stents were similar in the incidence of mortality， cardiac mortality， MACE， MI， TVR and ST in the treatment of CHD. SES could significantly reduce the incidence of target lesion revascularization compared with ZES， but sensitivity analysis showed that above mentioned results were instable.

Key words: coronary disease, drugeluting stents, sirolimus, meatanalysis